Formula I CDK4/6 Inhibitors for Cell Cycle Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies lack effective small molecule inhibitors for CDK4 and CDK6, which are crucial for regulating cell cycle progression and are often overexpressed in cancer, leading to uncontrolled cell proliferation.
Innovation Solution
Development of compounds of Formula I, which are designed to inhibit CDK4 and CDK6 by targeting specific structural features, including various substituents and ring configurations, to disrupt the kinase activity of these enzymes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapies are used, then treatment is provided, but effective small molecule inhibitors for CDK4 and CDK6 are lacking
Solution Approach 1:
The patent applies parameter changes by systematically varying molecular parameters including ring size (4-9 membered), heteroatom composition (O, S, NRb), substituent types (R1, R2, R4, R6 groups), and molecular configuration to optimize CDK4/6 inhibition. This enables the development of effective small molecule inhibitors where none previously existed, directly resolving the contradiction between therapeutic effectiveness and availability of inhibitors.
2Reliability
If CDK4/6 are inhibited, then cell cycle progression is controlled, but specific structural features must be targeted
Solution Approach 1:
The patent segments the inhibitor molecule into distinct functional components: a core ring structure (ring A or ring B), heteroatom positions (Z), and multiple substituent positions (R1, R2, R4, R6). This segmentation allows systematic optimization of each component to achieve reliable CDK4/6 inhibition while managing molecular complexity through modular design.
Solution Approach 2:
The patent applies local quality by assigning specific properties to different regions of the molecule: ring A provides a 4-9 membered cycloalkyl or heterocycloalkyl core, ring B provides a 5-membered heteroaryl structure, Z provides heteroatom functionality (O, S, NRb), and R groups provide diverse substituent properties. This localized functional assignment enables precise targeting of CDK4/6 while organizing molecular complexity into manageable segments.
Data Source
AI summary
The disclosure is directed to compounds of Formula Ipharmaceutical compositions comprising compounds of Formula I, as well as methods of their use and preparation, are also described.